ASCO 2026: InnoCare Pharma's Mesutoclax Achieves 100% Overall Response Rate in Treatment-Naïve MDS
InnoCare Pharma (HKEx: 09969; SSE: 688428) presented updated clinical data on its novel BCL2 inhibit...
Johnson & Johnson Releases Nipocalimab Data for Sjögren's Syndrome, Response Rate Reaches 62.5% in High Autoantibody Subgroup
On June 3, Johnson & Johnson announced new exploratory biomarker analyses from the Phase 2 DAHLI...
China's Chen Lei Establishes World's First Female Epilepsy Diagnosis and Treatment Ontology Database, Infertility Rate Drops to 12.8%
Chen Lei, Vice Dean of West China Clinical Medical College of Sichuan University, Chief Physician an...
Johnson & Johnson's Nipocalimab Meets Primary Endpoint in Phase 2 Study for Systemic Lupus Erythematosus
Johnson & Johnson presented detailed results from the Phase 2 JASMINE study of the FcRn blocker nipo...
Germany's FundaMental Pharma Appoints Chief Medical Officer
FundaMental Pharma GmbH announced the appointment of Dr. Hans Eriksson as Chief Medical Officer, whe...
Asahi Kasei Life Science Licenses ADC Technology from Noguchi Institute
Asahi Kasei Life Science announced a technology licensing and collaboration agreement with the Noguc...
US-based RayzeBio Plans $150 Million Investment in Radiopharmaceutical Facility
On June 1, RayzeBio, a subsidiary of Bristol Myers Squibb, announced plans to invest approximately $...
Zhejiang, China Launches 225Ac-PSMA Clinical Study for Prostate Cancer and Completes First Patient Dosing
The Department of Nuclear Medicine at Zhejiang Cancer Hospital recently initiated an international m...
U.S. Bio-IT World Focuses on AI Drug Discovery, Collaborative Intelligence Becomes New Variable in Life Sciences R&D
In the keynote speeches on the second day of the 2026 Bio-IT World conference, multiple experts disc...
UK's Quotient Sciences Initiates Phase I Clinical Trial of AI-Designed Formulation
Quotient Sciences has initiated a clinical study to evaluate a novel drug product developed using ar...